Article
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Breast cancer research and treatment - 1 Jan 2010
Ellis Matthew J, Lin Li, Crowder Robert, Tao Yu, Hoog Jeremy, Snider Jacqueline, Davies Sherri, DeSchryver Katherine, Evans Dean B, Steinseifer Jutta, Bandaru Raj, Liu WeiHua, Gardner Humphrey, Semiglazov Vladimir, Watson Mark, Hunt Kelly, Olson John, Baselga José
Abstract excerpt
Mutations in the alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA) occur in approximately 30% of ER positive breast cancers. We therefore sought to determine the impact of PIK3CA mutation on response to neoadjuvant endocrine therapy. Exons 9 (helical domain) and 20 (kinase domain-KD) mutations in PIK3CA were determined samples from four neoadjuvant endocrine therapy trials.Interactions with clinical,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.